Pancreatic acinar cell: Its role in acute pancreatitis

被引:53
作者
Leung, Po Sing [1 ]
Ip, Siu Po
机构
[1] Chinese Univ Hong Kong, Fac Med, Dept Physiol, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Sch Chinese Med, Shatin, Hong Kong, Peoples R China
关键词
renin-angiotensin system; digestive enzymes; acute pancreatitis; exocrine pancreas;
D O I
10.1016/j.biocel.2005.12.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The pancreatic acinar cell is the functional unit of the exocrine pancreas. It synthesizes, stores, and secretes digestive enzymes. Under normal physiological conditions, digestive enzymes are activated only once they have reached the duodenum. Premature activation of these enzymes within pancreatic acinar cells leads to the onset of acute pancreatitis; it is the major clinical disorder associated with pancreatic acinar cells. Although there have been major advances in our understanding of the pathogenesis of this disease in recent years, available treatment options are still limited to traditional nonspecific and palliative interventions. Novel therapeutic strategies have been suggested based on ongoing research in the physiology and pathophysiology of the disease; these include the administration of systemic antibiotics, antioxidants, cytokine antagonists, and more recently, inhibition of the renin-angiotensin system. Notwithstanding this promising development, most of these potential therapies are still in an experimental stage or clinical trial. Further investigation is needed to prove the efficacy of these novel treatment modalities. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1024 / 1030
页数:7
相关论文
共 26 条
[1]   Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis [J].
Bhatia, M ;
Ramnath, RD ;
Chevali, L ;
Guglielmotti, A .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2005, 288 (06) :G1259-G1265
[2]  
BOCKMAN DE, 1980, CELL TISSUE RES, V205, P445
[3]  
Bockman DE, 1997, MICROSC RES TECHNIQ, V37, P509, DOI 10.1002/(SICI)1097-0029(19970601)37:5/6<509::AID-JEMT13>3.0.CO
[4]  
2-U
[5]   Current management of acute pancreatitis [J].
Clancy, TE ;
Benoit, EP ;
Ashley, SW .
JOURNAL OF GASTROINTESTINAL SURGERY, 2005, 9 (03) :440-452
[6]   Reduction in the development of cerulein-induced acute pancreatitis by treatment with M40401, a new selective superoxide dismutase mimetic [J].
Cuzzocrea, S ;
Genovese, T ;
Mazzon, E ;
Di Paola, R ;
Muià, C ;
Britti, D ;
Salvemini, D .
SHOCK, 2004, 22 (03) :254-261
[7]  
Fishman MP, 2002, INT J DEV BIOL, V46, P201
[8]  
Gomez-Cambronero L. G., 2002, Current Drug Targets - Inflammation and Allergy, V1, P393, DOI 10.2174/1568010023344544
[9]   Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis:: A placebo-controlled, double-blind trial [J].
Isenmann, R ;
Rünzi, M ;
Kron, M ;
Kahl, S ;
Kraus, D ;
Jung, N ;
Maier, L ;
Malfertheiner, P ;
Goebell, H ;
Beger, HG .
GASTROENTEROLOGY, 2004, 126 (04) :997-1004
[10]   Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis [J].
Johnson, CD ;
Kingsnorth, AN ;
Imrie, CW ;
McMahon, MJ ;
Neoptolemos, JP ;
McKay, C ;
Toh, SKC ;
Skaife, P ;
Leeder, PC ;
Wilson, P ;
Larvin, M ;
Curtis, LD .
GUT, 2001, 48 (01) :62-69